A new study has found that since the early 1990s, half a million poor and working class middle-aged White people in the United States have been killed by suicide, alcohol and drug poisoning, and alcohol-related liver disease. As The Atlantic reports, these are diseases of despair. This is a crisis of epidemic proportions rooted in social and economic inequities, but it’s not only White people who are affected. In fact, despite the focus of The Atlantic, the New York Times, and other media outlets on White lives, the study reveals that Black lives continue to be lost to these diseases at much greater rates. And while these deaths have been rising in the United States, in other countries with universal, publicly financed healthcare and strong safety nets, the study finds, such deaths have been falling continuously for the last twenty-five years.
5,500% increase in drug price draws widespread condemnation
A company recently drew widespread condemnation for buying the rights to a 62-year-old drug and increasing the price per tablet from $13.50 to $750 overnight. Several years ago, each pill was priced at just $1. Patients rely on the drug, Daraprim, to treat an infection that commonly affects people whose immune systems have been compromised by AIDS and some forms of cancer. The company sparked moral outrage, but it was operating both legally and rationally within a capitalist system in which healthcare is treated as a profitable commodity rather than as a human right. In the past year, several state legislatures have considered “pharmaceutical cost transparency bills” that would require drug companies to justify the prices they charge for medications. The bills would be a step in the right direction, but while transparency is an important part of a human-rights-based healthcare system, the bills would still leave much power over people’s access to healthcare in the hands of the pharmaceutical industry, and would do less to guarantee people’s access to medications than bulk purchasing, price controls, allowing imports, requiring drugs developed with public research funding be sold as generics, and other measures.
Mergers, collapse of coops and rate hikes highlight problems with the private insurance model
Three trends have developed this fall that illuminate structural problems with the private insurance model that remains under the Affordable Care Act. First, two planned mergers being considered by the Justice Department would consolidate control over the healthcare of 42% of the population in the hands of just three gargantuan insurance companies. The insurance industry mergers are mirrored by at least 78 hospital mergers so far this year and a similar “merger frenzy” among pharmacies and drug makers. In a related trend, a dozen nonprofit insurance “coops” have collapsed. The coops, which had offered insurance plans in many states, have been unable to compete against the insurance giants’ deep pockets and market power. And most recently, states have given insurance companies the green light to raise insurance premiums for publicly subsidized insurance plans by an average of 7.5% nationally and, for some plans, by more than 20%. At the same time, insurance companies are reporting that they will increase premiums on unsubsidized individual and small-group insurance plans by even more. The rate increases are all based on insurance companies’ profit motives, not on people’s ability to pay or their right to healthcare, and States have approved the increases with minimal transparency, participation and accountability.